You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for Patent: 11,234,954

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,234,954 protect, and when does it expire?

Patent 11,234,954 protects SILENOR and is included in one NDA.

This patent has eleven patent family members in four countries.

Summary for Patent: 11,234,954

Title:	Low-dose doxepin for treatment of sleep disorders in elderly patients
Abstract:	Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.
Inventor(s):	Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan Ellen (Carlsbad, CA), Jochelson; Philip (San Diego, CA), Kavey; Neil Barton (Chappaqua, NY)
Assignee:	Currax Pharmaceuticals LLC (Brentwood, TN)
Application Number:	14/789,911
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 11,234,954

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-001	Mar 17, 2010	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF INSOMNIA	⤷ Try a Trial
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF INSOMNIA	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,234,954

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2687118	⤷ Try a Trial
Canada	2687124	⤷ Try a Trial
European Patent Office	2026792	⤷ Try a Trial
Japan	2009537553	⤷ Try a Trial
Japan	2009537554	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.